ArticleZhongguo fei ai za zhi = Chinese journal of lung cancer2017
[Effect of Adjuvant Chemotherapy on DFS for Patients with Stage I NSCLC].
Article in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 6 citations in OpenAlex.
- Adjuvant chemotherapy in pathological node-negative non-small cell lung cancer.Scientific reports · 2023Article
- Prognostic Value of Chromatin Structure Typing in Early-Stage Non-Small Cell Lung Cancer.Cancers · 2023Article
- Clinical efficacy of adjuvant chemotherapy in stage IB (< 4 cm) non-small cell lung cancer patients with high-risk factors.The Korean journal of internal medicine · 2022Article
- Prognostic value of positron emission tomography in resected stage IA non-small cell lung cancer.European radiology · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSurgical resection is the best choice for early lung cancer, but the prognosis of early postoperative lung cancer is still very different, whether or not to apply adjuvant chemotherapy is controversial. This study examines the role of postoperative adjuvant chemotherapy in patients with stage I non-small cell lung cancer (NSCLC), particularly in high-risk groups.
methodsPatients with pathologic stage Ia and stage Ib NSCLC who underwent complete (R0) resection between January 2009 and June 2013 were identified from Peking University People's Hospital and classified into two groups based on postoperative chemotherapy or not. Kaplan-Meier and Log-rank tests were used to compare disease free survival (DFS). Scored according to the number of risk factors, all patients were divided into three groups. Kaplan-Meier and Log-rank tests were used to compare DFS between them. The effect of postoperative chemotherapy on high-risk group was observed individually.
resultsA total of 465 patients including 284 cases of stage Ia and 181 cases of stage Ib were enrolled in this study. For stage Ia there was no significant difference between the chemotherapy group and the control group in DFS (P=0.171), but the survival curve of the chemotherapy group was located below the control group. For stage Ib there was no significant difference between the two groups either (P=0.630). But there were significant differences on DFS between the three groups according to the number of risk factors (P<0.001). The more risk factors mean the worse DFS. However, independent analyses showed no significant effect of postoperative chemotherapy on DFS in the high-risk group patients (P=0.763).
conclusionsPostoperative chemotherapy does not have a positive effect on DFS in early stage non-small cell lung cancer, and chemotherapy may not be appropriate even for patients with multiple risk factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.